10,284 reports of this reaction
1.7% of all CETIRIZINE HYDROCHLORIDE reports
#11 most reported adverse reaction
ALOPECIA is the #11 most commonly reported adverse reaction for CETIRIZINE HYDROCHLORIDE, manufactured by Kenvue Brands LLC. There are 10,284 FDA adverse event reports linking CETIRIZINE HYDROCHLORIDE to ALOPECIA. This represents approximately 1.7% of all 615,076 adverse event reports for this drug.
Patients taking CETIRIZINE HYDROCHLORIDE who experience alopecia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ALOPECIA is a less commonly reported adverse event for CETIRIZINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to alopecia, the following adverse reactions have been reported for CETIRIZINE HYDROCHLORIDE:
The following drugs have also been linked to alopecia in FDA adverse event reports:
ALOPECIA has been reported as an adverse event in 10,284 FDA reports for CETIRIZINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ALOPECIA accounts for approximately 1.7% of all adverse event reports for CETIRIZINE HYDROCHLORIDE, making it a notable side effect.
If you experience alopecia while taking CETIRIZINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.